The effects of estrogen, its antagonist ICI 182, 780, and interferon-tau on the expression of estrogen receptors and integrin alphaV beta 3 on cycle day 16 in bovine endometrium.
We have shown previously that downregulation of intercaruncular stromal integrin alphavbeta3 in bovine endometrium on day 16 of the estrous cycle coincided with the antibody recognition of estrogen receptors (ER) in the luminal epithelium. In pregnancy, these changes were not observed. Our hypothesis was that on day 16 of the estrous cycle, estrogen from the dominant follicle causes a reduction in integrin alphavbeta3 and affects ERalpha in the luminal epithelium. The pregnancy recognition protein, interferon-tau (IFN-tau), may prevent downregulation of integrin alphavbeta3 and suppress ERalpha expression in the luminal epithelium. On days 14 to 16, heifers received uterine infusions of the anti-estrogen ICI 182, 780, estradiol 17beta, IFN-tau or the saline control. On day 16, reproductive tracts were collected for analysis of integrin alphavbeta3 and ERalpha. Estrogen receptor alpha immunoreactivity was largely restricted to the luminal epithelium in control animals. Using anti-ERalpha recognizing the amino terminus, estrogen-treated animals showed reactivity in the stroma, shallow and deep glands and myometrium as is typical of estrus, whereas ICI 182, 870 treated heifers showed little or no reactivity. In contrast, carboxyl terminus-directed antibodies showed a widespread distribution of ERalpha with reactivity detected in the uterine epithelium, stroma and myometrium of both estrogen and ICI 182, 780 treated animals. Heifers treated with IFN-tau had low ERalpha reactivity overall. Control and IFN-tau treated heifers had lower intercaruncular stromal expression of integrin alphavbeta3 in comparison to estrogen and ICI 182, 780 treatments. Overall, the results suggest that on day 16 of the estrous cycle, estrogen effects on integrin alphavbeta3 are indirect and do not directly involve ERalpha in the luminal epithelium. During pregnancy, interferon-tau may block ERalpha in the luminal epithelium but likely does not rescue integrin alphavbeta3 expression.
Kimmins
Sarah
S
Department of Plant and Animal Sciences, Nova Scotia Agricultural College, Truro, Nova Scotia, Canada. s2kimmins@nsac.ns.ca
Russell
Gerald L
GL
Lim
Hai Choo
HC
Hall
Brian K
BK
MacLaren
Leslie A
LA
D000818:Animals; D002417:Cattle; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D004847:Epithelial Cells / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D047628:Estrogen Receptor alpha; D030762:Estrous Cycle / Q000502:physiology*; D005260:Female; D000077267:Fulvestrant; D005786:Gene Expression Regulation / Q000187:drug effects; D039302:Integrin alphaVbeta3 / Q000096:biosynthesis* / Q000235:genetics; D007370:Interferon Type I / Q000494:pharmacology; D009215:Myometrium / Q000378:metabolism / Q000648:ultrastructure; D006080:Ovarian Follicle / Q000378:metabolism; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000096:biosynthesis* / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D017154:Stromal Cells / Q000378:metabolism
D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D039302:Integrin alphaVbeta3; D007370:Interferon Type I; D011257:Pregnancy Proteins; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011994:Recombinant Proteins; C020947:interferon tau; D000077267:Fulvestrant; D004958:Estradiol